Balancing Timelines and Ensuring Quality: A CDMO Expert Discusses Technology Transfer Challenges in Cell and Gene Therapy

In a recent interview with EPR editor Caroline Peachey at Terrapin’s Advanced Therapies conference in London, Roberto Formisano, Process Transfer Senior Manager at AGC Biologics, discussed the challenges associated with technology transfer in the cell and gene therapy industry. He shared his insights on the complexities involved in transferring technology from development to GMP manufacturing, as well as from a customer to a contract development and manufacturing organization (CDMO).

Roberto highlighted the critical timelines that present the biggest challenges in the field of technology transfer. He explained how balancing the number of batches that need to be manufactured is essential to ensuring sufficient and scientifically quality data within these timelines.

During his conversation with Caroline Peachey, Roberto also shared his insights on the technology and manufacturing trends and priorities that he foresees for the cell and gene therapy industry in 2024. He delved into the nuances of technology transfer and its implications for the industry.